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Abstract
Seventy-eight dogs with pain from hip dysplasia participated in a six-month placebo-controlled,
double-blinded clinical trial of gold bead implantation. In the present, non-blinded study, 73 of these
dogs were followed for an additional 18 months to evaluate the long-term pain-relieving effect of
gold bead implantation. The recently-published results of the six month period revealed that 30 of
the 36 dogs (83%) in the gold implantation group showed significant improvement (p = 0.02),
included improved mobility and reduction in the signs of pain, compared to the placebo group (60%
improvement).
In the long-term two-year follow-up study, 66 of the 73 dogs had gold implantation and seven dogs
continued as a control group. The 32 dogs in the original placebo group had gold beads implanted
and were followed for a further 18 months. A certified veterinary acupuncturist used the same
procedure to insert the gold beads as in the blinded study, and the owners completed the same
type of detailed questionnaires. As in the blinded study, one investigator was responsible for all the
assessments of each dog. The present study revealed that the pain-relieving effect of gold bead
implantation observed in the blinded study continued throughout the two-year follow-up period.
Background
Hip-joint arthritis, mostly from canine hip dysplasia
(CHD), is a common, non-curable and painful disease
amongst medium and large breed dogs [1-4] and therapy
is palliative at best [5].
Implantation of gold beads in both humans and animals
with arthritis was first attempted by veterinary traditional
acupuncturists [6]. Other researchers [7,8] who implanted
gold beads in dogs, observed no clinical effect after six-
and three-months study periods. However, in a recent
paper we revealed that gold bead implantation had a sig-
nificant pain-relieving effect in a six months controlled,
double-blinded clinical trial [9]. The initial mean pain
scores in the gold-bead implantation and control groups
were 5.6 and 4.8, respectively, where 0 was no pain and 10
was extreme pain. After 3 months the mean pain scores
were significantly reduced in both groups. After six
months, no further reduction had taken place in the con-
trol group, while a significant further reduction in mean
pain score (to 1.9) was found in the gold group. The total
reduction in mean pain score was in the gold group 65%
compared to 36% in the placebo group (p < 0.01). Each
dog's overall response, according to its owner's impres-
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sion of change in mobility, lameness, stiffness and behav-
iour at home, scored on a six-point Likert scale, showed a
significant improvement (p = 0.02) in 30 of the 36 dogs
(83%) in the gold implantation group compared to 60%
improvement in the placebo group [9].
The aim of the present study was to evaluate whether the
significant improvement that we found after six months
was still present 24 months after gold bead implantation.
Materials and methods
Study design
The study was carried out as a randomised, placebo-con-
trolled and double blind clinical trial with stratified paral-
lell group design for six months (Jaeger and others 2005),
and then as an open follow-up study for 18 months. All
dogs with a history of pain and/or lameness or dysfunc-
tion of the hind limbs due to hip dysplasia and with no
previous acupuncture history were invited to the study.
The diagnosis of hip dysplasia was based on radiographs
and was graded as mild, moderate or severe according to
the guidelines of the Scientific Commission of the Nordic
Kennel Union, and Federation Cynologique Internation-
ale. The dogs were owned privately and lived in private
households with their owners for the entire trial period,
and none of the owners had more than one dog in the
trial.
The treatment was blinded for both the owners and the
responsible clinical investigator during the first six
months of the trial period. The randomisation code was
then broken and the placebo-treated dogs were offered
gold bead implantation, after which the open study fol-
lowed. The implantation procedure was identical to that
used at the commencement of the trial. The dogs were
divided into three groups (Table 1). The GG group con-
sisted of dogs treated with gold bead implantation from
Day 0 and followed for a total of two years. The PG group
was formed from dogs that were initially in the placebo
group, were treated with gold bead at six months and then
followed for a further 18 months. The PC group was ini-
tially in the placebo group and was followed for a further
18 months without any gold bead implantation.
Animals
In the double-blind study 38 and 42 dogs were allocated
to gold bead implantation and to placebo treatment,
respectively [9,10]. During this period two dogs from the
gold implantation group discontinued for reasons unre-
lated to the treatment (drop outs). After the randomiza-
tion code was broken, 73 of the 78 dogs that completed
the six month study were followed for further 18 months;
the present study. Of the 42 dogs in the placebo group in
the six-month study, 33 received gold bead implantation
and nine continued in the 18-month follow-up period as
a control PC group (Table 1). The 18-month follow-up
groups consisted of 30 males and 43 females, with a mean
age and weight of 6.3 years and 35.5 kg. The mean dura-
tion of gold bead implantation was 21.6 months at the
end of the study. Two of the 36 dogs originally treated
with gold implantation (GG group) dropped out and two
were euthanized on the owners' request due to insuffi-
cient pain-relieving effect (withdrawals) during the study
period. Of the 33 dogs in the PG group, one dropped out,
two were euthanized (withdrawals) and one was with-
drawn for unknown reasons. Of the nine dogs in the PC
group, two dropped out.
Clinical procedure
An IVAS (International Veterinary Acupuncture Society)-
certified acupuncturist performed the gold bead implanta-
tion. The same investigator as in the six-month blind trial
was responsible for the follow-up period and performed
all assessments of each dog. Owners were questioned
about their dog's clinical signs and medical history using
the same standardized questionnaire as for the six-month
Table 1: Number of dogs (n) with mild/moderate or severe hip dysplasia divided into three different weight groups, where the hip 
status and body weights are used as stratification factors.
Treatment group Number of dogs (n) Drop Out (n) Weight group (kg) Mild or Moderate hip dysplasia (n) Severe hip dysplasia (n) Total (n)
GG 36 2 ≤ 20.0 1 3 4
20.1 – 34.9 8 8 16
≥ 35.0 8 6 14
PG 33 1 ≤ 20.0 0 1 1
20.1 – 34.9 7 9 16
≥ 35.0 10 5 15
PC 9 2 ≤ 20.0 0 0 0
20.1 – 34.9 4 0 4
≥ 35.0 0 3 3
Total 78 5 38 35 73
The GG group = gold implantation from Day 0 to 24 months, the PG group = placebo treatment the first six blinded month and then 18 months 
gold bead implantation, PC group = placebo treatment the first six blinded month and as a control group the next 18 monthsActa Veterinaria Scandinavica 2007, 49:9 http://www.actavetscand.com/content/49/1/9
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blinded period. The same examination procedure includ-
ing videotaping the dogs in five different gaits was used.
Hip radiographs and blood samples were taken at the end
of the 18-month follow-up period.
The veterinarian's assessment of pain was based on the
response to rotation, flexion and extension of the affected
hip, and graded on a 4-point scale, where "no pain
response" = 1, "mild pain response", tries to move away =
2, "moderate pain response", turns head toward the hip,
slight vocalization = 3 and "large pain response", turns
head with intention to bite, howls = 4 [11]. Each hip was
given a separate score and then both added to a total hip
score.
During assessment, each dog was videotaped walking,
trotting before and after stretch/extension of each hip, and
performing left and right turns. Lameness was graded on
a 5-point scale for each gait and scored as "no lameness"
= 0, "barely disturbed locomotion" = 1, " locomotion dis-
turbed but limb(s) still bearing weight" = 2, "lameness
with limb(s) not always bearing weight" = 3, "no weight
bearing on limb(s)" = 4 [12]. A total lameness score was
calculated by adding the scores for the four gaits at each
examination.
Each dog's overall response, derived from to its owner's
general impression of change in mobility, lameness, stiff-
ness and behaviour at home and during different types of
exercise, was scored on a six-point Likert scale [13], where
"large deterioration" = 1, "mild deterioration" = 2, "no
change in signs" = 3, "mild improvement" = 4, "large
improvement" = 5 and "without any signs of hip dyspla-
sia" = 6.
The owners were asked to assess their dog's quality of life,
taking into consideration its ability to fulfil its physical,
mental and social needs, and signs of pain and dysfunc-
tion, as poor, fairly good or very good.
The owners were asked to give their opinions of the pain-
relieving effect of gold bead implantation, regardless of
the duration of effect, as one of four alternatives: no effect,
small effect, good effect or very good effect.
Use of palliative medication
Owners were allowed to administer other forms of pallia-
tive treatment if their dog needed it. In such cases only
non-steroid anti-inflammatory drugs (NSAIDs) were used
and it was recorded.
Statistical analysis
Dogs that discontinued the study due to reasons related to
the treatment (withdrawals) were included in the analysis,
using the procedure of last observation carried forward.
All assumed continuously-distributed factors and varia-
bles were expressed as mean values with 95% confidence
interval (CI) calculated in accordance with the Student
procedure [14]. Discontinuously-distributed factors and
variables were expressed in contingency tables [15].
Comparisons of groups with regard to assumed continu-
ously-distributed variables were performed with Analysis
of Variance (ANOVA), with repeated measurements and
initial scores as covariate [16]. Matched-pairs ANOVA
model was used for analysis within groups.
For change within groups, cross-table analysis was per-
formed [15].
All comparisons between groups, and changes within
groups, were performed two-tailed with a significance
level of 5%.
Results
The mean hip-pain score recorded by the clinical investi-
gator in the pooled gold implantation group was signifi-
cantly reduced (p < 0.01) from day 0 to 24 months (Table
2). In the PC group an increased mean hip-pain score was
detected in the same period, although this was not signif-
icant (p = 0.28). The change in mean hip pain score was
significantly larger in the pooled gold implantation group
compared to the PC group (p = 0.012).
The mean lameness score observed by the clinical investi-
gator was reduced from day 0 to 24 months in the pooled
gold bead implantation group (p = 0.09) and numerically
increased in the PC group (p = 0.84) in the same period
(Table 2). The change in mean lameness score between
Table 2: Mean hip-pain score and mean lameness score (95% CI) at Day 0 and 24 months in the pooled gold implantation group 
evaluated by the clinical investigator.
Time GG +PG (pooled) (n = 66) PC (n = 7)
Pain score Day 0 4.8 (4.5 – 5.2) 4.4 (2.9 – 5.9)
24 months 4.2 (3.8 – 4.6) 5.0 (3.9 – 6.1)
Lameness score Day 0 1.9 (1.3 – 2.6) 2.6 (0.6 – 4.6)
24 months 1.2 (0.5 – 1.8) 3.0 (0.7 – 5.3)
For abbreviations see Table 1Acta Veterinaria Scandinavica 2007, 49:9 http://www.actavetscand.com/content/49/1/9
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the groups was not significant. Thirty-four of the 66 dogs
in the pooled gold bead implantation group were initially
recorded as lame, with a total lameness score of 127. After
24 months, the number had decreased to eighteen dogs
with a total lameness score of 76. In the PC group, five of
seven dogs were initially recorded as lame, with a total
lameness score of 18; after 24 months two dogs were still
lame, but had increased the total lameness score to 21.
The changes reported by the owners more or less mim-
icked those recorded by the clinical assessor. The hip-pain
score in the pooled gold implantation group, reported by
the owners, was significantly reduced (p < 0.01) during
the 24 months period (Table 3). A reduction was also
detected in the PC group, but this was not found signifi-
cant (p = 0.06). The reduction in the pooled gold implan-
tation group was larger then in the PC group, but the
difference was not significant (p = 0.13).
The degree of dysfunction, reported by the owners, was
significantly reduced (p < 0.01) in the pooled gold
implantation group during the study (Table 3). No
change was detected in the PC group (p = 0.74), and the
reduction in dysfunction in the pooled gold implantation
group was found to be significantly larger than in PC
group (p < 0.01).
Table 4 shows the changes (improvement or deteriora-
tion) in the dog's behaviour from hip-pain, according to
the owner's impression, for the different treatment
groups. A significant improvement in the signs of hip-
pain (p < 0.01) was found in the pooled gold bead
implantation group, compared to the PC group in the
period from day 0 to 24 months. The prevalence of dogs
in the pooled GG and PG groups that demonstrated
improvements after 24 months of treatment was 81.8%
(CI 70.4 – 90.2) (Table 4). The improvement was found
to be less in the PG-group compared to the GG-group (p
= 0.05). However, the PG-group showed a significant bet-
ter improvement compared to the PC group (p = 0.03).
The scores for overall hip-pain improvement or deteriora-
tion according to the owner's impression of their dog's
behaviour after six months and 24 month for the GG
group is given in Table 5. Owner-reports indicated that
85.3% (CI 68.9 – 95.1) of the dogs with gold bead
implantation from Day 0 showed improvements in the
overall hip-pain score after six months of treatment. After
24 months, 94.1% (CI 80.3 – 99.3) of the dogs with gold
bead implantation showed improvements, but the
increase was not found statistically significant. It can be
seen from the Table 5 that 15 dogs (the bold numbers)
were unchanged in their hip-pain scores when the scores
at six and 24 months were compared. Nine dogs showed
a further improvement from six to 24 months, eight dogs
had reduced improvements and two dogs showed deteri-
oration.
In Table 6 the owners' assessments of their dogs' quality
of life after 24 months is shown. The prevalence of "very
good" quality of life in the pooled gold bead implantation
groups was 63.6% (50.9 – 75.1), while the corresponding
value for the GG group was 70.6% (52.5–84.9) and for
the PC group 71.4% (29.0–96.3).
Table 3: Owners' assessments of hip pain and dysfunction using a 10 cm visual analog scale from 0 – 10 where 0 = no pain or 
dysfunction and 10 = extreme pain or dysfunction. The results are expressed as mean values with a 95% confidence interval.
Time GG +PG (pooled) (n = 66) PC Group (n = 7)
Pain signs Day 0 5.1 (4.8 – 5.4) 4.4 (3.4 – 5.5)
24 months 2.4 (1.8 – 2.9) 3.0 (1.2 – 4.8)
Dysfunction Day 0 4.3 (3.9 – 4.7) 3.9 (3.0 – 4.7)
24 months 2.2 (1.6 – 2.7) 4.0 (2.3 – 5.7)
For abbreviations see Table 1
Table 4: Number of dogs treated with gold implantation and a control group that showed changes in the signs of hip dysplasia, 
according to their owners' general impressions of their dog's behaviour in its daily life after 24 months of treatment.
Treatment 
group
No pain signs Large improvement 
in signs
Moderate 
improvement in 
signs
No change in 
signs
Moderate 
deterioration in 
signs
Severe 
deterioration in 
signs
Total
GG 3 19 10 0 2 0 34
P G 11 2 925 3 3 2
GG+PG 
(pooled)
43 1 1 9 27 3 6 6
P C  ( c o n t r o l ) 0 0 124 0 7
For abbreviations see Table 1Acta Veterinaria Scandinavica 2007, 49:9 http://www.actavetscand.com/content/49/1/9
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When asked their opinion of the pain-relieving effect of
gold bead implantation, 100% (CI 89.7 – 100.0) of own-
ers of dogs in the GG group reported a good or very good
effect, while the corresponding value for the PG group was
78.1% (CI 60.0 – 90.7). Small or no effect was reported by
21.9% (CI 9.3 – 40.0). Pooling the two gold implantation
groups produced a value of 89.4% (CI 79.4 – 95.6) of
owners that reported good or very good effect.
At the termination of the study, or at time of death, the
owners were asked if they had observed a positive pain-
relieving effect of the gold bead implantation, and if so,
for how long. Continuous pain-relieving effect of gold
bead implantation was reported in 79.7% (CI 68.3 –
88.4) of the dogs. If a dog went with gold implantation for
20 months for example, and showed a positive effect for
18 of these months, the recorded duration of effect was
90%. The mean duration of effect for gold-implanted
dogs was 90.7% (CI 87.5 – 94.1; range 17.5% to 100.0%).
Use of NSAIDS was recorded in the period between six
and 24 months. Three of 34 dogs (CI 1.9 – 23.7) in the
GG group reported use of NSAIDs periodically or daily
after appearance of pain signs, whereof one dog was with-
drawn. Seven of 32 dogs (CI 9.3 – 40.0) in the PG group
reported use of NSAIDs periodically or daily after appear-
ance of pain, whereof two dogs were withdrawn. Two of
seven dogs in the PC group reported use of NSAIDs peri-
odically or daily. No significant difference was detected
between these groups.
Discussion
The same pain-relieving effect that was revealed in the
blind six-month study [9] continued in the open study of
gold implantation, as assessed by both the owners and the
clinical investigator. The result is very promising, but not
unexpected on the basis of the results from the six-month
blinded study. It is, however, remarkable that a one-time
Table 5: Number of dogs in a cross table with different scores for the overall hip pain improvement or deterioration according to the 
owners' general impression of their dog's behaviour in its daily life after six and 24 months in the originally gold implantation group. 
Evaluation of hip pain signs after 24 months
Owner's 
assessment → ↓
No pain 
signs
Large 
improvement 
in signs
Moderate 
improvement 
in signs
No change in 
signs
Moderate 
deterioration 
in signs
Severe 
deterioration 
in signs
Total
Evaluation of hip 
pain signs after 6 
months
No pain signs 1 31000 5
Large improvement 2 10 4000 1 6
Moderate 
Improvement
04 4 000 8
No change 0 2 1 0 20 5
Moderate 
deterioration
0 0000 00
Severe 
deterioration
0 00000 0
Total 3 19 10 0 2 0 34
The last row of the table shows the situation after six months, and the last column the results after 24 months. The bold figures display no change 
in hip pain signs or dysfunction from six months to 24 months. Figures to the right and left of the bold figures express the deterioration and 
ameliorations, respectively.
Table 6: Owners assessments of their dog's quality of life after 24 months in the pooled (GG+PG) group treated with gold bead 
implantation and in the control group.
Quality of life after 24 months
Treatment group Very Good Fairly good Poor Total
GG/PG (pooled) 42 18 6 66
GG 24 7 3 34
P C  ( c o n t r o l ) 5207
For abbreviations see Table 1.Acta Veterinaria Scandinavica 2007, 49:9 http://www.actavetscand.com/content/49/1/9
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implantation of gold beads should have a sustained pain-
relieving effect over so many months.
This clinical trial was originally an attempt to model the
pain-relieving effect of gold-bead implantation in
humans with degenerative arthritis. In humans, a two-
year period of medical follow-up is rather brief, seen in
relation to presumptive duration of life. Dogs with a mean
lifespan ten times less than man [17], undergo similar
age-related diseases. The expected lifespan of a newborn
dog is 5–7 years [17] and two years represents roughly
25% of its expected duration of life.
The largest weakness with the present study is that it was
non-blinded during the last 18 months, with both the
owner and the clinical investigator being aware of the
treatment. The results may therefore have been biased in
a positive direction by the evaluators, as in any other non-
blinded clinical trials [18], and the clinical evaluation of
improvement or deterioration will to a certain degree be
affected by the owner's enthusiastic or disappointed atti-
tude. To reduce this possible bias, standardized and care-
fully-designed questionnaires were used.
The pain-relieving effect in the 24 months follow-up study
that was recorded by both the owner and the clinical
investigator was, however, slightly smaller than in the
blind six months study. Perhaps the owners belonging to
the originally placebo group were more sceptical since a
majority of them had earlier believed that their dogs had
received gold implantation, and now reported more cau-
tious results [10]. This is in accordance with other studies
[19,20], since there is a strong placebo effect in the blind
study and probably a nocebo effect in the open study.
Non-blinded studies usually over-estimate treatment
effect by about 17% [21]. However, the present study is
not comparable with a simple non-blinded study, since
this study started as a blinded study that later crossed over
to a non-blinded study.
Another limitation with the present study is that the con-
trol group without gold implantation was small and con-
sisted probably of dogs whose owners were satisfied with
their animal's clinical performance and level of pain. To
entice owners to complete the study, the owners of the 42
dogs in the original placebo group were promised gold
bead implantation when the randomization code was
broken, if their dogs still had pain signs due to hip-joint
arthritis. Thirty-three owners accepted gold bead implan-
tation, leaving only nine dogs in the subsequent control
group, and two of these dropped out. It is possible that the
remaining dogs in the control group had minimal pain
signs and therefore represent a selection bias. If so, the dif-
ferences in pain between the pooled gold-bead implanta-
tion group and the control group could be expected to be
smaller than in a double blind study.
There were five withdrawals from the pooled gold implan-
tation group in the follow-up study, due to inadequate
pain-relieving effect. These dogs were included in the
analysis of the results.
Pain-relieving medications were only used by approxi-
mately 16% of the dogs and equally distributed in all
groups, and likely not to have influenced to the overall
results.
The cause and the mechanisms of the pain-relieving effect
were not investigated in the present study and need to be
explored in detail in future studies.
Conclusion
A positive, long-term and sustained palliative effect of
gold-bead implantation in dogs with hip dysplasia has
been demonstrated, which needs to be confirmed in a
new, placebo-controlled blind study.
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